Trial Search Results
Transplantation for Patients With Chronic Lymphocytic Leukemia
To evaluate the role of high dose therapy and autologous or allogeneic hematopoietic cell transplantation for the treatment of chronic lymphocytic leukemia.
Stanford is currently not accepting patients for this trial.
Lead Sponsor:
Stanford University
Stanford Investigator(s):
Intervention(s):
- Procedure: high dose chemotherapy then autologous hematopoietic cell transplant
- Procedure: ablative allogeneic hematopoietic cell transplant
Phase:
N/A
Eligibility
Inclusion Criteria:- adequate organ function - normal bone marrow cytogenetics
Exclusion Criteria:- active CNS disease
- For autologous patients more than 30% bone marrow involvement
Ages Eligible for Study
18 Years - 60 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
BMT Referrals
6507230822
Not Recruiting